WallStSmart
ANTX

AN2 Therapeutics Inc

NASDAQ: ANTX · HEALTHCARE · BIOTECHNOLOGY

$4.27
-8.39% today

Updated 2026-06-05

Market cap
$176.84M
P/E ratio
P/S ratio
EPS (TTM)
$-1.14
Dividend yield
52W range
$1 – $7
Volume
0.3M

AN2 Therapeutics Inc (ANTX) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item2019202020212022202320242025
Revenue$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)
Cost of revenue$77000.00
Gross profit$-77000.00
Gross margin
R&D$29.33M$6.02M$16.91M$29.51M$54.87M$40.49M$24.77M
SG&A$1.73M$1.26M$4.67M$12.75M$14.76M$14.07M$13.34M
Operating income$-31.07M$-7.28M$-21.57M$-42.26M$-69.64M$-54.55M$-38.11M
Operating margin
EBITDA$-5.18M$-7.28M$-21.47M$-43.47M$4.90M$3.23M$-38.11M
EBITDA margin
EBIT$-36.25M$-7.28M$-21.57M$-42.26M$-64.73M$-51.32M
Interest expense$0.00$3000.00$69000.00$514000.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-33.81M$-13.60M$-21.47M$-41.47M$-64.73M$-51.32M$-35.17M
Net income growth (YoY)+59.8%-57.9%-93.1%-56.1%+20.7%+31.5%
Profit margin

Frequently asked questions

How much free cash flow does ANTX generate?

ANTX produced $-29.83M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is ANTX's balance sheet healthy?

ANTX holds $19.94M in cash and equivalents against — in long-term debt, on $53.06M of shareholder equity. That debt is best read against the cash flow the business throws off each year.